CML, Refractory
3 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS (NCT03884829) | Cyclacel Pharmaceuticals, Inc. | 2019-03-25 |
| A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs (NCT03459534) | Il-Yang Pharm. Co., Ltd. | 2018-06-25 |
| Expanded Access to Vodobatinib for Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Not Responded to Previous Treatments (NCT07517315) | Sun Pharma Advanced Research Company Limited |
Track CML, Refractory automatically
Every clearance here is in the API, with alerts when new ones post.